
  
    
      
        Introduction_NNP
        In_IN patients_NNS with_IN ARDS_NNP and_CC acute_JJ pulmonary_JJ hypertension_NN ,_,
        inhaled_JJ NO_DT has_VBZ been_VBN shown_VBN to_TO selectively_RB dilate_NN pulmonary_JJ
        vessels_NNS perfusing_VBG ventilated_VBN lung_NN areas_NNS ,_, and_CC to_TO improve_VB
        arterial_NN oxygenation_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. The_DT
        `_`` plateau_NN '_'' effect_NN of_IN NO_DT on_IN pulmonary_JJ vascular_NN resistance_NN and_CC
        gas_NN exchange_NN is_VBZ obtained_VBN at_IN various_JJ concentrations_NNS ranging_VBG
        from_IN 1_CD -_: 40_CD ppm_NN [_NN 2_CD ,_, 4_CD ,_, 6_CD ,_, 7_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. In_IN the_DT majority_NN of_IN
        patients_NNS ,_, a_DT major_JJ improvement_NN in_IN arterial_NN oxygenation_NN can_MD
        be_VB obtained_VBN with_IN NO_DT concentrations_NNS <_NN 5_CD ppm_NN [_NN 4_CD ,_, 9_CD ,_, 10_CD ,_,
        11_CD ]_NN ._. In_IN addition_NN ,_, the_DT degree_NN of_IN response_NN as_RB well_RB as_IN the_DT
        optimal_NN NO_DT dose_NN varies_VBZ both_DT between_IN individuals_NNS and_CC from_IN
        day_NN to_TO day_NN [_NN 11_CD ]_NN ._. In_IN sheep_NN with_IN experimental_JJ acute_JJ lung_NN
        injury_NN receiving_VBG inhaled_JJ NO_DT ,_, a_DT dose-dependent_JJ increase_NN in_IN
        arterial_NN oxygenations_NNS is_VBZ found_VBN ,_, with_IN a_DT plateau_NN effect_NN at_IN NO_DT
        concentrations_NNS of_IN 30_CD -_: 60_CD ppm_NN [_NN 12_CD ,_, 13_CD ]_NN ._. Nitric_NNP oxide_NN
        concentrations_NNS >_NN 30_CD ppm_NN may_MD result_VB in_IN elevated_VBD
        concentrations_NNS of_IN nitrogen_NN dioxide_NN (_( NO_DT 
        2_LS )_) and_CC methemoglobin_NN particularly_RB when_WRB
        100_CD %_NN oxygen_NN is_VBZ administered_VBN together_RB with_IN NO_DT [_NN 9_CD ]_NN ._. Because_IN
        of_IN the_DT potential_JJ lung_NN toxicity_NN of_IN NO_DT 
        2_CD ,_, knowledge_NN of_IN the_DT factors_NNS influencing_VBG
        the_DT optimal_NN dose_NN of_IN inhaled_JJ NO_DT in_IN humans_NNS is_VBZ of_IN critical_JJ
        importance_NN for_IN intensivists_NNS ._. Recently_RB ,_, it_PRP has_VBZ been_VBN
        suggested_VBN that_IN the_DT presence_NN of_IN septic_JJ shock_NN may_MD decrease_VB
        responsiveness_NNS to_TO inhaled_JJ NO_DT [_NN 14_CD ]_NN :_: among_IN 25_CD patients_NNS with_IN
        ARDS_NNP and_CC septic_JJ shock_NN ,_, only_RB 40_CD %_NN responded_VBD to_TO inhaled_JJ NO_DT
        with_IN an_DT improvement_NN in_IN PaO_NNP 
        2_CD /_NN FiO_NNP 
        2_CD ≥_NN 20_CD %_NN ._. This_DT proportion_NN was_VBD estimated_VBN as_IN
        `_`` abnormally_RB low_JJ '_POS ,_, although_IN there_EX are_VBP no_DT published_VBN data_NN
        reporting_VBG the_DT proportion_NN of_IN non-septic_JJ patients_NNS with_IN ARDS_NNP
        responding_VBG to_TO inhaled_JJ NO_DT by_IN an_DT increase_NN in_IN PaO_NNP 
        2_CD /_NN FiO_NNP 
        2_CD >_NN 20_CD %_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP
        hypothesized_VBN that_IN the_DT presence_NN of_IN septic_JJ shock_NN and_CC the_DT
        administration_NN of_IN vasoconstrictors_NNS to_TO patients_NNS with_IN ARDS_NNP
        could_MD modify_VB the_DT dose-response_JJ to_TO inhaled_JJ NO_DT ._. We_PRP wanted_VBD to_TO
        assess_VB whether_IN in_IN NO-responding_NNP patients_NNS with_IN septic_JJ shock_NN ,_,
        higher_JJR NO_DT concentrations_NNS were_VBD required_VBN to_TO obtain_VB a_DT
        pulmonary_JJ effect_NN similar_JJ to_TO the_DT one_CD obtained_VBN in_IN non-septic_JJ
        patients_NNS ._. In_IN addition_NN ,_, the_DT effect_NN of_IN intravenous_JJ
        norepinephrine_NN on_IN an_DT NO-induced_NNP decrease_NN in_IN pulmonary_JJ
        artery_NN pressure_NN and_CC increase_NN in_IN arterial_NN oxygenation_NN was_VBD
        investigated_VBN ._. Therefore_RB ,_, dose-response_JJ studies_NNS were_VBD
        performed_VBN on_IN two_CD groups_NNS of_IN critically_RB ill_JJ patients_NNS with_IN and_CC
        without_IN septic_JJ shock_NN whose_WP$ lungs_NNS were_VBD mechanically_RB
        ventilated_VBN for_IN ARDS_NNP ._. All_DT patients_NNS enrolled_VBD were_VBD NO_DT
        responders_NNS and_CC patients_NNS with_IN septic_JJ shock_NN were_VBD exclusively_RB
        receiving_VBG intravenous_JJ norepinephrine_NN for_IN hemodynamic_JJ
        support_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS
          During_IN an_DT 8_CD month_NN period_NN ,_, 29_CD consecutive_JJ hypoxemic_JJ
          patients_NNS with_IN ARDS_NNP ,_, diagnosed_VBN on_IN or_CC after_IN admission_NN to_TO
          the_DT Surgical_NNP Intensive_NNP Care_NNP Unit_NNP (_( SICU_NNP )_) of_IN La_NNP Pitié_NNP
          Hospital_NNP in_IN Paris_NNP (_( Department_NNP of_IN Anesthesiology_NNP )_) ,_, were_VBD
          prospectively_RB screened_VBD at_IN an_DT early_JJ stage_NN of_IN their_PRP$
          respiratory_JJ disease_NN ._. Written_VBN informed_VBN consent_NN was_VBD
          obtained_VBN from_IN the_DT patient_NN 's_POS next_JJ of_IN kin_NN ._. The_DT study_NN was_VBD
          approved_VBN by_IN the_DT Comité_NNP Consultatif_NNP de_IN Protection_NNP des_NNP
          Personnes_NNP dans_NNS la_FW Recherche_NNP Biomédicale_NNP of_IN La_NNP
          Pitié-_NNP Salpétrière_NNP Hospital_NNP ._.
          Inclusion_NNP criteria_NNS were_VBD :_:
          1_LS ._. bilateral_JJ infiltrates_NNS on_IN a_DT bedside_NN chest_NN
          radiograph_NN ;_:
          2_LS ._. PaO_NNP 
          2_CD ≤_NN 200_CD mmHg_NN using_VBG an_DT FiO_NNP 
          2_CD of_IN 1_CD ._. 0_CD and_CC zero_CD end-expiratory_JJ
          pressure_NN (_( ZEEP_NNP )_) ;_:
          3_LS ._. bilateral_JJ and_CC extensive_JJ hyperdensities_NNS on_IN a_DT high_JJ
          resolution_NN spiral_NN thoracic_JJ CT_NNP scan_VB ;_:
          4_LS ._. positive_JJ response_NN to_TO inhaled_JJ NO_DT ,_, defined_VBN as_IN a_DT
          decrease_NN in_IN MPAP_NNP of_IN at_IN least_JJS 2_CD mmHg_NN and_CC an_DT increase_NN in_IN
          PaO_NNP 
          2_CD (_( FiO_NNP 
          2_CD 1_CD ._. 0_CD ,_, PEEP_NNP 10_CD cmH_NN 
          2_CD O_NNP )_) of_IN at_IN least_JJS 40_CD mmHg_NN after_IN NO_DT
          inhalation_NN at_IN an_DT inspiratory_NN concentration_NN of_IN 15_CD ppm_NN ._.
          These_DT response_NN criteria_NNS were_VBD fixed_VBN in_IN order_NN to_TO select_VB
          patients_NNS responding_VBG to_TO NO_DT by_IN a_DT decrease_NN in_IN MPAP_NNP and_CC an_DT
          increase_NN in_IN PaO_NNP 
          2_CD of_IN sufficient_JJ magnitude_NN to_TO allow_VB the_DT
          determination_NN of_IN dose-response_JJ curves_NNS ._. It_PRP was_VBD considered_VBN
          that_IN when_WRB the_DT variation_NN of_IN the_DT parameter_NN studied_VBN (_( either_CC
          PaO_NNP 
          2_CD or_CC pulmonary_JJ artery_NN pressure_NN )_) was_VBD
          close_VB or_CC inferior_JJ to_TO the_DT precision_NN of_IN measurement_NN ,_, it_PRP was_VBD
          not_RB possible_JJ to_TO accurately_RB assess_VB the_DT dose-response_JJ ._.
          Exclusion_NNP criteria_NNS were_VBD :_:
          1_LS ._. left_VBD ventricular_NN failure_NN ,_, defined_VBN as_IN a_DT cardiac_JJ
          index_NN ≤_NN 21_CD /_NN min_NN /_NN m_NN 2_CD associated_VBN with_IN a_DT pulmonary_JJ capillary_JJ
          wedge_NN pressure_NN >_NN 18_CD mmHg_NN and_CC /_NN or_CC a_DT left_VBN ventricular_NN
          ejection_NN fraction_NN <_NN 50_CD %_NN as_IN estimated_VBN by_IN bedside_NN
          transesophageal_NN echocardiography_NN ;_:
          2_LS ._. circulatory_NN shock_NN requiring_VBG an_DT exogenous_JJ
          catecholamine_NN other_JJ than_IN norepinephrine_NN ,_, or_CC characterized_VBN
          by_IN spontaneous_JJ fluctuations_NNS of_IN blood_NN pressure_NN despite_IN a_DT
          constant_JJ infusion_NN of_IN norepinephrine_NN ;_:
          3_LS ._. cardiac_JJ dysrhythmias_NNS ;_:
          4_LS ._. presence_NN of_IN a_DT patent_NN foramen_NN ovale_NN with_IN a_DT
          right-to-left_JJ atrial_NN shunt_NN as_IN assessed_VBN by_IN pulsed-wave_JJ
          Doppler_NNP transesophageal_NN echocardiography_NN ._.
          These_DT exclusion_NN criteria_NNS were_VBD intended_VBN to_TO eliminate_VB
          patients_NNS with_IN cardiac_JJ failure_NN ,_, intracardiac_NN shunt_NN or_CC
          cardiovascular_JJ instability_NN ,_, in_IN whom_WP an_DT accurate_JJ
          evaluation_NN of_IN dose-response_JJ to_TO inhaled_JJ NO_DT would_MD have_VB been_VBN
          either_CC difficult_JJ or_CC heavily_RB biased_VBN [_NN 15_CD ]_NN ._. Among_IN the_DT 29_CD
          patients_NNS initially_RB screened_VBD for_IN inclusion_NN ,_, 13_CD had_VBD to_TO be_VB
          excluded_VBN (_( no_DT response_NN to_TO NO_DT ,_, 
          n_NN =_SYM 6_CD ;_: left_VBD ventricular_NN failure_NN ,_, 
          n_NN =_SYM 4_CD ;_: circulatory_NN shock_NN with_IN an_DT
          unstable_JJ arterial_NN pressure_NN ,_, 
          n_NN =_SYM 2_CD ;_: atrial_NN fibrillation_NN ,_, 
          n_NN =_SYM 1_LS )_) ._. Finally_RB ,_, 16_CD patients_NNS
          fulfilling_VBG inclusion_NN and_CC exclusion_NN criteria_NNS were_VBD
          included_VBN ._. Eight_CD patients_NNS were_VBD in_IN septic_JJ shock_NN and_CC eight_CD
          patients_NNS had_VBD no_DT septic_JJ shock_NN ._. Diagnosis_NNP of_IN septic_JJ shock_NN
          was_VBD made_VBN according_VBG to_TO the_DT criteria_NNS of_IN the_DT American_NNP
          College_NNP of_IN Chest_NNP Physicians_NNPS /_NN Society_NNP of_IN Critical_JJ Care_NNP
          Medicine_NNP Consensus_NNP Conference_NNP [_NN 16_CD ]_NN ,_, requiring_VBG :_: (_( 1_LS )_) a_DT
          systemic_JJ response_NN to_TO infection_NN and_CC (_( 2_LS )_) a_DT systolic_JJ blood_NN
          pressure_NN <_NN 90_CD mmHg_NN despite_IN adequate_JJ fluid_JJ
          resuscitation_NN requiring_VBG vasopressor_NN agents_NNS ._. Adult_NNP
          respiratory_JJ distress_NN syndrome_NN was_VBD diagnosed_VBN according_VBG to_TO
          the_DT recent_JJ American-_NNP European_NNP Consensus_NNP Conference_NNP [_NN 17_CD ]_NN
          and_CC its_PRP$ severity_NN was_VBD graded_JJ according_VBG to_TO Murray_NNP 
          et_CC al_NN [_NN 18_CD ]_NN ._.
          In_IN each_DT patient_NN the_DT trachea_NN was_VBD orally_RB intubated_JJ with_IN
          a_DT HiLo_NNP Jet_NNP TMno_NNP 8_CD Mallinckrodt_NNP tube_NN (_( Inc_NNP ,_, Argyle_NNP ,_, NY_NNP )_)
          which_WDT incorporates_VBZ two_CD side_NN ports_NNS ,_, one_CD ending_VBG at_IN the_DT
          distal_NN tip_NN of_IN the_DT endotracheal_NN tube_NN and_CC a_DT more_JJR proximal_NN
          port_NN ending_VBG 6_CD cm_NN from_IN the_DT tip_NN ._. These_DT additional_JJ channels_NNS
          were_VBD used_VBN for_IN continuous_JJ monitoring_NN of_IN tracheal_NN pressure_NN
          and_CC tracheal_NN concentrations_NNS of_IN inhaled_JJ NO_UH ._. After_IN
          inclusion_NN in_IN the_DT study_NN ,_, all_DT patients_NNS were_VBD sedated_JJ and_CC
          paralysed_JJ with_IN a_DT continuous_JJ intravenous_JJ infusion_NN of_IN
          fentanyl_NN 250_CD μg_NN /_NN h_NN ,_, flunitrazepam_NN 1_CD mg_NN /_NN h_NN and_CC vecuronium_NN 4_CD
          mg_NN /_NN h_NN ,_, and_CC their_PRP$ lungs_NNS were_VBD ventilated_VBN using_VBG conventional_JJ
          mechanical_JJ ventilation_NN (_( César_NNP Ventilator_NNP ,_, Taema_NNP ,_, France_NNP )_) ._.
          For_IN each_DT patient_NN ,_, tidal_JJ volume_NN and_CC respiratory_JJ rate_NN were_VBD
          adjusted_VBN to_TO maintain_VB constant_JJ minute_NN ventilation_NN
          throughout_IN the_DT study_NN ._. An_DT inspiratory_NN time_NN of_IN 30_CD %_NN ,_, a_DT PEEP_NNP
          of_IN 10_CD cmH_NN 
          2_CD O_NNP and_CC an_DT FiO_NNP 
          2_CD of_IN 0_CD ._. 85_CD were_VBD maintained_VBN throughout_IN
          the_DT study_NN period_NN ._. FiO_NNP 
          2_CD was_VBD continuously_RB monitored_VBN ,_, using_VBG an_DT
          O_NNP 
          2_CD analyser_NN (_( Sérès_NNP 4000_CD
          Aix-en-_NNP Provence_NNP ,_, France_NNP )_) ,_, in_IN order_NN to_TO detect_VB changes_NNS
          resulting_VBG from_IN the_DT admixture_NN of_IN inspired_VBN gases_NNS with_IN NO_UH ._.
          All_DT patients_NNS were_VBD monitored_VBN using_VBG a_DT fiberoptic_JJ
          thermodilution_NN pulmonary_JJ artery_NN catheter_NN (_( Oximetrix_NNP
          Opticath_NNP Catheter_NNP ,_, Abbot_NNP Critical_JJ Care_NNP System_NNP )_) and_CC a_DT
          radial_NN or_CC femoral_NN arterial_NN catheter_NN ._.
          In_IN order_NN to_TO accurately_RB assess_VB the_DT extension_NN of_IN
          pulmonar_NN hyperdensities_NNS ,_, and_CC thereby_RB the_DT severity_NN of_IN ARDS_NNP
          patients_NNS were_VBD transported_VBN to_TO the_DT Department_NNP of_IN Radiology_NNP
          (_( Thoracic_NNP Division_NNP )_) for_IN a_DT lung_NN scan_VB ._. The_DT scan_VB was_VBD
          performed_VBN from_IN the_DT apex_NN to_TO the_DT diaphragm_NN using_VBG a_DT Tomoscan_NNP
          SR_NNP 7000_CD (_( Philips_NNP ,_, Eindhoven_NNP )_) and_CC a_DT semi-quantitative_JJ
          assessment_NN of_IN parenchymal_NN consolidation_NN in_IN ZEEP_NNP was_VBD
          performed_VBN according_VBG to_TO a_DT technique_NN previously_RB described_VBD [_NN
          4_CD ,_, 5_CD ,_, 8_CD ,_, 9_CD ]_NN ._. CT_NNP scans_NNS were_VBD obtained_VBN in_IN all_DT patients_NNS
          except_IN patient_NN 8_CD who_WP could_MD not_RB be_VB transported_VBN to_TO the_DT
          Department_NNP of_IN Radiology_NNP because_IN of_IN an_DT unstable_JJ pelvic_JJ
          fracture_NN ._.
        
        
          Measurements_NNP
          Systolic_NNP and_CC diastolic_JJ arterial_NN pressures_NNS (_( SAP_NNP and_CC
          DAP_NNP )_) ,_, and_CC systolic_JJ and_CC diastolic_JJ pulmonary_JJ arterial_NN
          pressures_NNS (_( SPAP_NNP and_CC DPAP_NNP )_) were_VBD simultaneously_RB measured_VBN
          using_VBG the_DT arterial_NN cannula_NN and_CC the_DT fiberoptic_JJ pulmonary_JJ
          artery_NN catheter_NN connected_VBN to_TO two_CD calibrated_VBN pressure_NN
          transducers_NNS (_( 91_CD DPT-_NNP 308_CD Mallinckrodt_NNP )_) positioned_VBN at_IN the_DT
          midaxillary_JJ line_NN ._. Systemic_NNP and_CC pulmonary_JJ arterial_NN
          pressures_NNS ,_, electrocardiogram_NN (_( EKG_NNP )_) ,_, tracheal_NN pressure_NN
          (_( Paw_NNP )_) measured_VBN through_IN the_DT distal_NN port_NN of_IN the_DT
          endotracheal_NN tube_NN ,_, and_CC gas_NN flow_NN and_CC tidal_JJ volume_NN (_( V_NNP 
          T_NN )_) measured_VBN using_VBG a_DT heated_JJ and_CC
          calibrated_VBN Hans_NNP Rudolph_NNP pneumotachograph_NN ,_, were_VBD
          simultaneously_RB and_CC continuously_RB recorded_VBN on_IN a_DT Gould_NNP ES_NNP
          1000_CD recorder_NN (_( Gould_NNP Instruments_NNP ,_, Cleveland_NNP ,_, OH_NNP )_)
          throughout_IN the_DT entire_JJ study_NN period_NN ,_, at_IN a_DT paper_NN speed_NN of_IN 1_CD
          mm_NN /_NN s_VBZ ._.
          In_IN all_DT patients_NNS ,_, expired_VBD CO_NNP 
          2_CD was_VBD measured_VBN using_VBG a_DT nonaspirative_JJ
          calibrated_VBN 47210_CD A_DT infrared_JJ capnometer_NN (_( Hewlett_NNP Packard_NNP )_)
          positioned_VBN between_IN the_DT proximal_NN end_NN of_IN the_DT endotracheal_NN
          tube_NN and_CC the_DT Y_NNP piece_NN of_IN the_DT ventilator_NN ._. Expired_NNP CO_NNP 
          2_CD curves_NNS were_VBD continuously_RB recorded_VBN on_IN
          the_DT Gould_NNP ES_NNP 1000_CD recorder_NN at_IN a_DT paper_NN speed_NN of_IN 1_CD mm_NN /_NN s_VBZ ._.
          After_IN withdrawing_VBG an_DT arterial_NN blood_NN sample_NN ,_, the_DT ratio_NN of_IN
          alveolar_NN dead_JJ space_NN (_( VD_NNP 
          A_DT )_) to_TO V_NNP 
          T_NN was_VBD calculated_VBN as_IN :_:
          VD_NNP 
          A_DT /_NN V_NNP 
          T_NN =_SYM 1_CD -_: (_( P_NN 
          ET_NNP CO_NNP 
          2_CD /_NN PaCO_NNP 
          2_LS )_)
          where_WRB P_NN 
          ET_NNP CO_NNP 
          2_CD is_VBZ end-tidal_JJ CO_NNP 
          2_CD measured_VBN at_IN the_DT plateau_NN of_IN the_DT
          expired_VBN CO_NNP 
          2_CD curve_NN ._. Expired_NNP CO_NNP 
          2_CD curves_NNS were_VBD then_RB recorded_VBN at_IN a_DT paper_NN
          speed_NN of_IN 50_CD mm_NN /_NN s_VBZ ,_, and_CC only_RB tracings_NNS demonstrating_VBG a_DT clear_JJ
          end-expiratory_JJ plateau_NN ,_, defined_VBN as_IN a_DT constant_JJ CO_NNP 
          2_CD value_NN for_IN more_JJR than_IN 0_CD ._. 5_CD s_VBZ at_IN
          end-expiration_JJ ,_, were_VBD used_VBN to_TO determine_VB P_NN 
          ET_NNP CO_NNP 
          2_CD ._. In_IN patient_NN 11_CD ,_, VD_NNP 
          A_DT /_NN V_NNP 
          T_NN was_VBD not_RB calculated_VBN because_IN no_DT
          plateau_NN could_MD be_VB identified_VBN on_IN the_DT expired_VBN CO_NNP 
          2_CD curve_NN ._. Because_IN ARDS_NNP is_VBZ associated_VBN
          with_IN abnormalities_NNS of_IN the_DT pulmonary_JJ vasculature_NN (_( local_JJ
          thrombi_NN and_CC pulmonary_JJ vasoconstriction_NN at_IN the_DT early_JJ stage_NN
          and_CC vascular_NN remodeling_VBG at_IN the_DT late_JJ stage_NN )_) ,_, VD_NNP 
          A_DT /_NN V_NNP 
          T_NN can_MD be_VB considered_VBN as_IN a_DT better_JJR index_NN
          of_IN these_DT vascular_NN lesions_NNS than_IN physiologic_JJ dead_JJ space_NN
          calculated_VBN by_IN the_DT Bohr_NNP equation_NN which_WDT takes_VBZ into_IN account_NN
          the_DT anatomic_JJ dead_JJ space_NN [_NN 19_CD ]_NN ._.
          In_IN each_DT phase_NN (_( see_VB experimental_JJ protocol_NN )_) ,_, when_WRB a_DT
          steady_JJ state_NN was_VBD obtained_VBN -_: defined_VBN as_IN a_DT leveling_NN of_IN the_DT
          pulmonary_JJ arterial_NN pressure_NN -_: SAP_NNP ,_, DAP_NNP ,_, SPAP_NNP ,_, DPAP_NNP ,_,
          pulmonary_JJ capillary_JJ wedge_NN pressure_NN (_( PWP_NNP )_) ,_, right_JJ atrial_NN
          pressure_NN (_( RAP_NNP )_) ,_, V_NNP 
          T_NN ,_, Paw_NNP and_CC gas_NN flow_NN were_VBD recorded_VBN at_IN
          a_DT paper_NN speed_NN of_IN 50_CD mm_NN /_NN s_VBZ ._. Mean_VB arterial_NN pressure_NN (_( MAP_NNP )_)
          was_VBD calculated_VBN as_IN 1_CD /_NN 3_CD SAP_NNP +_NN 2_CD /_NN 3_CD DAP_NNP ._. Mean_VB pulmonary_JJ
          artery_NN pressure_NN was_VBD measured_VBN by_IN planimetry_NN as_IN the_DT mean_NN of_IN
          four_CD measurements_NNS performed_VBN at_IN end-expiration_JJ ._. Systolic_NNP
          arterial_NN pressure_NN ,_, DAP_NNP ,_, SPAP_NNP ,_, DPAP_NNP ,_, PWP_NNP and_CC RAP_NNP were_VBD also_RB
          measured_VBN at_IN end-expiration_JJ ._. Cardiac_NNP output_NN was_VBD measured_VBN
          using_VBG the_DT thermodilution_NN technique_NN and_CC a_DT bedside_NN computer_NN
          allowing_VBG the_DT recording_NN of_IN each_DT thermodilution_NN curve_NN
          (_( Oximetrix_NNP 3_CD SO_NNP 
          2_CD /_NN CO_NNP Computer_NNP )_) ._. Four_CD serial_NN 10_CD ml_NN
          injections_NNS of_IN 5_CD %_NN dextrose_NN solution_NN at_IN room_NN temperature_NN
          were_VBD performed_VBN at_IN random_JJ during_IN the_DT respiratory_JJ cycle_NN [_NN
          20_CD ]_NN ._. Systemic_NNP and_CC pulmonary_JJ arterial_NN blood_NN samples_NNS were_VBD
          simultaneously_RB withdrawn_VBN within_IN 1_CD min_NN following_VBG cardiac_JJ
          output_NN measurements_NNS (_( after_IN discarding_VBG an_DT initial_JJ 10_CD ml_NN
          heparin_NN contaminated_JJ aliquot_NN )_) ._. Arterial_NNP pH_NN ,_, PaO_NNP 
          2_CD ,_, mixed_JJ venous_JJ partial_JJ pressure_NN of_IN
          oxygen_NN (_( PvO_NNP 
          2_LS )_) and_CC PaCO_NNP 
          2_CD were_VBD measured_VBN using_VBG an_DT IL_NNP BGE_NNP
          TMblood_NNP gas_NN analyser_NN ._. Hemoglobin_NNP concentration_NN ,_,
          methemoglobin_NN concentration_NN ,_, and_CC arterial_NN and_CC mixed_JJ
          venous_JJ oxygen_NN saturations_NNS (_( SaO_NNP 
          2_CD and_CC SvO_NNP 
          2_LS )_) were_VBD measured_VBN using_VBG a_DT calibrated_VBN
          OSM_NNP 3_CD hemoximeter_NN ._. Arterial_NNP and_CC mixed_JJ venous_JJ blood_NN samples_NNS
          that_WDT showed_VBD hemoglobin_NN concentrations_NNS differing_VBG by_IN more_JJR
          than_IN 0_CD ._. 1_CD g_SYM /_NN 100_CD ml_NN were_VBD considered_VBN diluted_VBN ,_, and_CC the_DT
          highest_JJS hemoglobin_NN concentration_NN was_VBD used_VBN to_TO calculate_VB
          oxygen_NN content_NN ._. Standard_JJ formulae_NN were_VBD used_VBN to_TO calculate_VB
          cardiac_JJ index_NN (_( CI_NNP )_) ,_, PVRI_NNP ,_, systemic_JJ vascular_NN resistance_NN
          index_NN (_( SVRI_NNP )_) ,_, right_JJ ventricular_NN stroke_NN work_NN index_NN
          (_( RVSWI_NNP )_) ,_, venous_JJ admixture_NN (_( Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN )_) ,_, arteriovenous_JJ oxygen_NN difference_NN
          [_NN C_NNP (_( av_NN )_) O_NNP 
          2_CD ]_NN ,_, oxygen_NN delivery_NN (_( DO_NNP 
          2_LS )_) ,_, oxygen_NN extraction_NN ratio_NN (_( EaO_NNP 
          2_LS )_) and_CC oxygen_NN consumption_NN (_( VO_NNP 
          2_LS )_) ._.
          In_IN all_DT patients_NNS ,_, respiratory_JJ pressure-volume_JJ (_( P-V_NNP )_)
          curves_NNS were_VBD measured_VBN using_VBG a_DT 1_CD l_NN syringe_NN (_( Model_NNP Series_NNP
          5540_CD ,_, Hans_NNP Rudolph_NNP Inc_NNP ,_, Kansas_NNP City_NNP ,_, MO_NNP )_) according_VBG to_TO a_DT
          previously_RB described_VBN technique_NN [_NN 8_CD ]_NN ._. Construction_NNP of_IN
          inspiratory_NN and_CC expiratory_NN P-V_NNP curves_NNS allowed_VBN :_:
          determination_NN of_IN opening_VBG pressure_NN (_( Pop_NNP )_) ,_, static_JJ
          respiratory_JJ compliance_NN (_( Crs_NNP )_) calculated_VBN as_IN the_DT slope_NN of_IN
          the_DT curve_NN between_IN 500_CD -_: 1000_CD ml_NN ,_, and_CC quasi-static_JJ
          respiratory_JJ compliance_NN (_( Cqs_NNP )_) ,_, obtained_VBN by_IN dividing_VBG the_DT V_NNP 
          T_NN by_IN the_DT corresponding_JJ airway_NN
          pressure_NN ._. Opening_NN pressure_NN could_MD be_VB clearly_RB identified_VBN in_IN
          nine_CD patients_NNS and_CC was_VBD always_RB ≤_NN 10_CD cmH_NN 
          2_CD O_NNP ._. A_DT PEEP_NNP of_IN 10_CD cmH_NN 
          2_CD O_NNP was_VBD systematically_RB applied_VBN to_TO all_DT
          patients_NNS ._.
        
        
          Nitric_NNP oxide_NN administration_NN
          Nitric_NNP oxide_NN was_VBD released_VBN from_IN three_CD different_JJ tanks_NNS
          of_IN nitrogen_NN that_WDT had_VBD NO_DT concentrations_NNS of_IN 25_CD ,_, 900_CD and_CC
          2000_CD ppm_NN ,_, measured_VBN using_VBG chemiluminescence_NN (_( Air_NNP Liquide_NNP ,_,
          France_NNP )_) ._. Nitric_NNP oxide_NN was_VBD delivered_VBN into_IN the_DT inspiratory_NN
          limb_NN of_IN the_DT ventilator_NN just_RB after_IN the_DT Fisher-_NNP Paykel_NNP
          humidifier_NN ,_, according_VBG to_TO a_DT previously_RB described_VBN technique_NN
          [_NN 9_CD ]_NN ._. With_IN the_DT aid_NN of_IN a_DT calibrated_VBN and_CC heated_JJ
          pneumotachograph_NN (_( Model_NNP Series_NN 3500_CD B_NNP ,_, Hans_NNP Rudolph_NNP Inc_NNP ,_,
          Kansas_NNP City_NNP ,_, MO_NNP )_) attached_VBN to_TO the_DT proximal_NN end_NN of_IN the_DT
          endotracheal_NN tube_NN ,_, V_NNP 
          T_NN was_VBD reduced_VBN to_TO exactly_RB compensate_VB
          for_IN the_DT added_VBN volume_NN of_IN nitrogen_NN and_CC NO_DT coming_VBG from_IN the_DT
          tank_NN ._. Thus_RB ,_, V_NNP 
          T_NN and_CC minute_NN ventilation_NN delivered_VBN to_TO
          the_DT patients_NNS were_VBD kept_VBN constant_JJ for_IN all_DT concentrations_NNS of_IN
          inhaled_JJ NO_UH ._.
          Inspiratory_NNP ,_, expiratory_NN and_CC mean_VB concentrations_NNS of_IN NO_DT
          and_CC NO_DT 
          2_CD were_VBD continuously_RB measured_VBN using_VBG a_DT
          fast_JJ response_NN time_NN chemiluminescence_NN apparatus_NN (_( NOX_NNP 4000_CD
          Sérès_NNP ,_, Aix-en-_NNP Provence_NNP ,_, France_NNP )_) ._. Intratracheal_NNP gas_NN was_VBD
          sampled_VBN by_IN continuous_JJ aspiration_NN through_IN the_DT proximal_NN
          side_NN port_NN of_IN the_DT Mallinckrodt_NNP endotracheal_NN tube_NN ,_, ie_NN 162_CD
          cm_NN from_IN the_DT site_NN of_IN NO_DT administration_NN ._. The_DT NOX_NNP 4000_CD is_VBZ a_DT
          chemiluminescence_NN apparatus_NN specifically_RB designed_VBD for_IN
          medical_JJ use_NN ._. When_WRB using_VBG an_DT aspiration_NN flow_NN rate_NN of_IN 150_CD
          ml_NN /_NN min_NN ,_, the_DT response_NN time_NN -_: defined_VBN as_IN the_DT time_NN necessary_JJ
          to_TO reach_VB 95_CD %_NN of_IN a_DT reference_NN NO_DT concentration_NN -_: is_VBZ around_IN
          30_CD s_VBZ and_CC only_RB mean_VB concentrations_NNS of_IN NO_DT can_MD be_VB accurately_RB
          measured_VBN ._. When_WRB an_DT aspiration_NN flow_NN rate_NN of_IN 1000_CD ml_NN /_NN min_NN is_VBZ
          selected_VBN ,_, the_DT response_NN time_NN is_VBZ 0_CD ._. 765_CD ms_NNS and_CC inspiratory_NN
          and_CC expiratory_NN NO_DT concentrations_NNS can_MD be_VB accurately_RB
          measured_VBN ._. In_IN a_DT previous_JJ study_NN ,_, we_PRP demonstrated_VBD that_DT
          inspiratory_NN and_CC expiratory_NN concentrations_NNS of_IN NO_DT were_VBD
          adequately_RB measured_VBN by_IN the_DT NOX_NNP 4000_CD with_IN a_DT precision_NN of_IN
          5_CD %_NN [_NN 9_CD ]_NN ._.
          During_IN the_DT study_NN ,_, inspiratory_NN and_CC expiratory_NN NO_DT
          concentrations_NNS were_VBD continuously_RB measured_VBN and_CC recorded_VBN
          after_IN setting_VBG the_DT aspiration_NN flow_NN rate_NN of_IN the_DT NOX_NNP 4000_CD at_IN
          1000_CD ml_NN /_NN min_NN ._. In_IN addition_NN ,_, in_IN steady_JJ state_NN conditions_NNS ,_,
          mean_VB intratracheal_NN NO_DT concentrations_NNS were_VBD measured_VBN by_IN
          setting_VBG the_DT aspiration_NN flow_NN rate_NN of_IN the_DT NOX_NNP 4000_CD at_IN 150_CD
          ml_NN /_NN min_NN ._. When_WRB the_DT aspiration_NN flow_NN rate_NN was_VBD changed_VBN ,_, the_DT
          tidal_JJ volume_NN setting_NN of_IN the_DT ventilator_NN was_VBD modified_VBN
          accordingly_RB in_IN order_NN to_TO achieve_VB a_DT constant_JJ minute_NN
          ventilation_NN and_CC stable_JJ NO_DT concentration_NN ._. In_IN order_NN to_TO
          increase_VB precision_NN ,_, two_CD different_JJ operating_NN ranges_NNS of_IN
          measurement_NN were_VBD used_VBN ,_, depending_VBG on_IN the_DT concentrations_NNS of_IN
          NO_DT administered_VBN to_TO the_DT patient_NN :_: an_DT operating_VBG range_NN of_IN 0_CD -_: 5_CD
          ppm_NN was_VBD selected_VBN for_IN inspiratory_NN tracheal_NN concentrations_NNS
          of_IN 0_CD ._. 15_CD ,_, 0_CD ._. 45_CD ,_, 1_CD ._. 5_CD and_CC 4_CD ._. 5_CD ppm_NN ,_, and_CC an_DT operating_VBG range_NN of_IN
          0_CD -_: 200_CD ppm_NN for_IN inspiratory_NN tracheal_NN concentrations_NNS of_IN 15_CD ,_,
          45_CD and_CC 150_CD ppm_NN ._. When_WRB 0_CD -_: 5_CD ppm_NN was_VBD selected_VBN ,_, calibration_NN
          was_VBD performed_VBN using_VBG a_DT tank_NN of_IN NO_DT with_IN a_DT reference_NN
          concentration_NN of_IN 0_CD ._. 945_CD ppm_NN (_( CFPO_NNP ,_, Air_NNP Liquide_NNP ,_, France_NNP )_) ;_:
          when_WRB 0_CD -_: 200_CD ppm_NN was_VBD selected_VBN ,_, calibration_NN was_VBD performed_VBN
          using_VBG a_DT tank_NN of_IN NO_DT with_IN a_DT reference_NN concentration_NN of_IN 22_CD ._. 8_CD
          ppm_NN (_( CFPO_NNP ,_, Air_NNP Liquide_NNP ,_, France_NNP )_) ._. Nitrogen_NNP oxides_NNS (_( NOX_NNP )_)
          were_VBD calibrated_VBN using_VBG the_DT same_JJ reference_NN tanks_NNS according_VBG
          to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. The_DT oxygen_NN analyser_NN
          of_IN the_DT NOX_NNP 4000_CD was_VBD used_VBN for_IN continuous_JJ monitoring_NN of_IN
          oxygen_NN concentration_NN in_IN order_NN to_TO ensure_VB that_IN a_DT constant_JJ
          FiO_NNP 
          2_CD was_VBD maintained_VBN during_IN NO_DT inhalation_NN ,_,
          whatever_WDT the_DT concentration_NN administered_VBN ._.
        
        
          Protocol_NNP
          
            Phase_NN 1_CD :_: PEEP_NNP without_IN NO_DT (_( control_NN 1_LS )_)
            Baseline_NNP measurements_NNS were_VBD made_VBN following_VBG a_DT 1_CD h_NN
            steady_JJ state_NN of_IN conventional_JJ mechanical_JJ ventilation_NN
            using_VBG the_DT following_NN ventilatory_NN settings_NNS :_: FiO_NNP 
            2_CD 0_CD ._. 85_CD ,_, PEEP_NNP 10_CD cmH_NN 
            2_CD O_NNP ,_, inspiratory_NN time_NN 30_CD %_NN ,_,
            respiratory_JJ frequency_NN 16_CD ±_NN 2_CD bpm_NN ,_, V_NNP 
            T_NN 728_CD ±_NN 32_CD ml_NN ._.
          
          
            Phase_NN 2_CD :_: PEEP_NNP 10_CD cm_NN H_NNP 2_CD O_NNP with_IN NO_DT at_IN increasing_VBG
            inspiratory_NN concentrations_NNS (_( dose-response_JJ curve_NN )_)
            Using_VBG the_DT same_JJ ventilatory_NN settings_NNS as_IN in_IN phase_NN 1_CD ,_,
            seven_CD inspiratory_NN tracheal_NN concentrations_NNS of_IN NO_DT ,_, chosen_VBN
            according_VBG to_TO a_DT logarithmic_JJ scale_NN ,_, were_VBD randomly_RB
            administered_VBN :_: 0_CD ._. 15_CD ,_, 0_CD ._. 45_CD ,_, 1_CD ._. 5_CD ,_, 4_CD ._. 5_CD ,_, 15_CD ,_, 45_CD and_CC 150_CD ppm_NN ._.
            Because_IN concentrations_NNS of_IN 45_CD and_CC 150_CD ppm_NN were_VBD
            associated_VBN with_IN a_DT longlasting_VBG increase_NN in_IN blood_NN
            methemoglobin_NN concentration_NN ,_, which_WDT interfered_VBD with_IN the_DT
            calculation_NN of_IN venous_JJ and_CC arterial_NN O_NNP 
            2_CD content_NN and_CC pulmonary_JJ shunt_NN ,_, they_PRP
            were_VBD not_RB included_VBN in_IN the_DT randomization_NN ,_, but_CC were_VBD always_RB
            administered_VBN as_IN the_DT last_JJ concentrations_NNS ._. For_IN each_DT
            inspiratory_NN tracheal_NN concentration_NN of_IN NO_DT ,_, expiratory_NN
            and_CC mean_VB intratracheal_NN concentrations_NNS of_IN NO_DT were_VBD
            measured_VBN and_CC recorded_VBN ._. In_IN addition_NN ,_, V_NNP 
            T_NN and_CC FiO_NNP 
            2_CD were_VBD adjusted_VBN at_IN the_DT ventilator_NN
            level_NN in_IN order_NN to_TO maintain_VB a_DT constant_JJ minute_NN
            ventilation_NN and_CC an_DT FiO_NNP 
            2_CD of_IN 0_CD ._. 85_CD as_IN assessed_VBN by_IN the_DT
            pneumotachograph_NN and_CC the_DT oxygen_NN analyser_NN ._. For_IN each_DT
            inspiratory_NN NO_DT concentration_NN ,_, hemodynamic_JJ and_CC
            respiratory_JJ measurements_NNS were_VBD recorded_VBN after_IN a_DT 15_CD min_NN
            steady_JJ state_NN ._.
          
          
            Phase_NN 3_CD :_: PEEP_NNP 10_CD cm_NN H_NNP 2_CD O_NNP without_IN NO_DT (_( control_NN
            2_LS )_)
            At_IN the_DT end_NN of_IN a_DT 1_CD h_NN steady_JJ state_NN following_VBG the_DT
            discontinuation_NN of_IN NO_DT 150_CD ppm_NN ,_, hemodynamic_JJ and_CC
            respiratory_JJ paramaters_NNS were_VBD measured_VBN at_IN the_DT same_JJ
            ventilator_NN settings_NNS as_IN in_IN phase_NN 1_CD ._.
          
        
        
          Statistical_NNP analysis_NN
          Cardiorespiratory_NNP parameters_NNS at_IN control_NN were_VBD compared_VBN
          between_IN groups_NNS using_VBG a_DT Student_NNP 's_POS 
          t_NN -_: test_NN for_IN unpaired_JJ data_NNS ._. The_DT
          cardiorespiratory_NN effects_NNS of_IN NO_DT were_VBD analysed_JJ in_IN each_DT
          group_NN using_VBG contrast_NN analysis_NN (_( control_NN values_NNS were_VBD
          compared_VBN with_IN values_NNS obtained_VBD using_VBG graded_JJ concentrations_NNS
          of_IN NO_DT )_) ._. In_IN both_DT groups_NNS of_IN patients_NNS ,_, the_DT existence_NN of_IN a_DT
          dose-related_JJ effect_NN was_VBD investigated_VBN using_VBG a_DT one-way_JJ
          analysis_NN of_IN variance_NN for_IN repeated_VBN measures_NNS including_VBG only_RB
          the_DT different_JJ concentrations_NNS of_IN NO_UH ._. Dose-response_NNP curves_NNS
          of_IN NO_DT on_IN hemodynamic_JJ and_CC respiratory_JJ parameters_NNS in_IN the_DT
          presence_NN or_CC absence_NN of_IN septic_JJ shock_NN were_VBD analysed_JJ using_VBG a_DT
          two-way_JJ analysis_NN of_IN variance_NN for_IN one_CD within_IN and_CC one_CD
          grouping_VBG factor_NN ,_, ie_NN factor_NN `_`` group_NN (_( absence_NN or_CC presence_NN of_IN
          septic_JJ shock_NN )_) '_POS and_CC factor_NN `_`` dose_NN of_IN NO_DT '_'' ._. Interaction_NNP
          between_IN these_DT two_CD factors_NNS allowed_VBD us_PRP to_TO test_VB the_DT
          hypothesis_NNS that_IN the_DT effect_NN of_IN NO_DT differed_VBD depending_VBG on_IN
          the_DT presence_NN or_CC absence_NN of_IN septic_JJ shock_NN ._. The_DT significance_NN
          level_NN was_VBD fixed_VBN at_IN 5_CD %_NN ,_, but_CC due_JJ to_TO the_DT nature_NN of_IN the_DT
          analysis_NN of_IN variance_NN ,_, we_PRP used_VBD the_DT criterion_NN of_IN Huynh_NNP and_CC
          Feld_NNP rather_RB than_IN the_DT classical_JJ F_NN value_NN [_NN 21_CD ]_NN ._.
          Calculations_NNP were_VBD made_VBN using_VBG Super_NNP ANOVA_NNP statistical_JJ
          software_NN (_( Abanus_NNP Concepts_NNP ,_, Inc_NNP )_) ._. All_DT values_NNS are_VBP expressed_VBN
          as_IN mean_NN ±_NN SEM_NNP ._.
        
      
      
        Results_NNS
        
          Patients_NNS
          Among_IN the_DT 16_CD men_NNS enrolled_VBD in_IN the_DT study_NN ,_, eight_CD were_VBD
          admitted_VBN to_TO the_DT SICU_NNP following_VBG multiple_JJ trauma_NN and_CC eight_CD
          following_VBG postoperative_JJ complications_NNS after_IN major_JJ
          surgical_JJ procedures_NNS (_( vascular_NN surgery_NN ,_, 
          n_NN =_SYM 1_CD ;_: cardiac_JJ surgery_NN ,_, 
          n_NN =_SYM 3_CD ;_: orthopedic_JJ surgery_NN ,_, 
          n_NN =_SYM 1_CD ;_: digestive_JJ surgery_NN ,_, 
          n_NN =_SYM 2_CD ;_: neurosurgery_NN ,_, 
          n_NN =_SYM 1_LS )_) ._. Eight_CD patients_NNS were_VBD in_IN
          septic_JJ shock_NN ,_, defined_VBN as_IN the_DT presence_NN of_IN an_DT identified_VBN
          infectious_JJ foci_NN associated_VBN with_IN arterial_NN hypotension_NN
          requiring_VBG the_DT continuous_JJ intravenous_JJ administration_NN of_IN
          norepinephrine_NN [_NN 16_CD ]_NN ._. Norepinephrine_NNP was_VBD administered_VBN in_IN
          doses_NNS ranging_VBG between_IN 1_CD and_CC 5_CD mg_NN /_NN h_NN ._. All_DT patients_NNS were_VBD
          studied_VBN at_IN the_DT early_JJ phase_NN of_IN ARDS_NNP (_( first_JJ 5_CD days_NNS )_) ._. As_IN
          shown_VBN in_IN Tables_NNP 1_CD and_CC 2_CD ,_, all_DT patients_NNS had_VBD ARDS_NNP
          characterized_VBN by_IN arterial_NN hypoxemia_NN ,_, increased_VBD Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN ,_, pulmonary_JJ artery_NN hypertension_NN ,_,
          reduced_VBD respiratory_JJ compliance_NN ,_, and_CC consolidation_NN of_IN lung_NN
          parenchyma_NN involving_VBG at_IN least_JJS 45_CD %_NN of_IN total_JJ lung_NN volume_NN ._.
          Initial_JJ clinical_JJ hemodynamic_JJ and_CC respiratory_JJ parameters_NNS
          were_VBD not_RB statistically_RB different_JJ between_IN patients_NNS with_IN
          and_CC without_IN septic_JJ shock_NN ._.
        
        
          NO_DT concentrations_NNS
          Table_NNP 3_CD shows_VBZ that_DT inspiratory_NN intratracheal_NN NO_DT
          concentrations_NNS were_VBD 1_CD ._. 5_CD -_: 2_CD times_NNS greater_JJR than_IN mean_VB
          intratracheal_NN NO_DT concentrations_NNS ._. Expiratory_NNP
          concentrations_NNS of_IN NO_DT progressively_RB increased_VBN with_IN mean_NN NO_DT
          concentrations_NNS ._. For_IN an_DT inspiratory_NN NO_DT concentration_NN of_IN
          0_CD ._. 15_CD ppm_NN ,_, expired_VBD NO_DT was_VBD not_RB detectable_JJ ._. For_IN an_DT
          inspiratory_NN NO_DT concentration_NN of_IN 0_CD ._. 45_CD ppm_NN ,_, expired_VBD NO_DT
          could_MD be_VB measured_VBN in_IN 15_CD patients_NNS ._. From_IN inspiratory_NN NO_DT
          concentrations_NNS of_IN 1_CD ._. 5_CD ppm_NN ,_, expired_VBD NO_DT could_MD be_VB measured_VBN
          in_IN all_DT patients_NNS ._.
        
        
          Hemodynamic_NNP and_CC respiratory_JJ effects_NNS of_IN NO_DT in_IN
          patients_NNS without_IN septic_JJ shock_NN
          As_IN shown_VBN in_IN Tables_NNP 4_CD and_CC 5_CD ,_, NO_DT induced_VBD a_DT significant_JJ
          dose-dependent_JJ decrease_NN in_IN MPAP_NNP ,_, SPAP_NNP ,_, DPAP_NNP ,_, PVRI_NNP ,_, RVSWI_NNP
          and_CC Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN with_IN a_DT significant_JJ and_CC
          dose-dependent_JJ increase_NN in_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD ._. 
          As_IN shown_VBN in_IN Figs_NNP 1_CD ,_, 2_CD ,_, 3_CD ,_, a_DT plateau_NN
          effect_NN was_VBD observed_VBN at_IN inspiratory_NN NO_DT concentrations_NNS of_IN
          4_CD ._. 5_CD ppm_NN for_IN MPAP_NNP ,_, PVRI_NNP ,_, Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN and_CC PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD ._. All_DT other_JJ hemodynamic_JJ and_CC
          respiratory_JJ parameters_NNS did_VBD not_RB vary_VB significantly_RB ._.
          Hemodynamic_NNP and_CC respiratory_JJ parameters_NNS returned_VBD to_TO
          control_VB values_NNS after_IN the_DT cessation_NN of_IN inhaled_JJ NO_UH ._.
        
        
          Hemodynamic_NNP and_CC respiratory_JJ effects_NNS of_IN NO_DT in_IN
          patients_NNS with_IN septic_JJ shock_NN
          Hemodynamic_NNP and_CC respiratory_JJ effects_NNS of_IN increasing_VBG
          inspiratory_NN concentrations_NNS of_IN NO_DT in_IN patients_NNS with_IN septic_JJ
          shock_NN are_VBP summarized_VBD in_IN Tables_NNP 6_CD and_CC 7_CD ._. A_DT significant_JJ
          dose-dependent_JJ decrease_NN in_IN SPAP_NNP ,_, DPAP_NNP ,_, MPAP_NNP ,_, PVRI_NNP ,_, RVSWI_NNP ,_,
          PaCO_NNP 
          2_CD ,_, VD_NNP 
          A_DT /_NN V_NNP 
          T_NN and_CC Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN and_CC a_DT significant_JJ dose-dependent_JJ
          increase_NN in_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD were_VBD observed_VBN ._. The_DT maximum_NN decrease_NN
          in_IN mean_NN PVRI_NNP ,_, PaCO_NNP 
          2_CD and_CC VD_NNP 
          A_DT /_NN V_NNP 
          T_NN was_VBD obtained_VBN for_IN an_DT inspiratory_NN NO_DT
          concentration_NN of_IN 4_CD ._. 5_CD ppm_NN (_( Fig_NNP 3_LS )_) ._. The_DT maximum_NN increase_NN in_IN
          PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD was_VBD obtained_VBN for_IN an_DT inspiratory_NN NO_DT
          concentration_NN of_IN 150_CD ppm_NN (_( Figs_NNP 1_CD and_CC 2_LS )_) ._. All_DT other_JJ
          hemodynamic_JJ and_CC respiratory_JJ parameters_NNS did_VBD not_RB vary_VB
          significantly_RB ._. Hemodynamic_NNP and_CC respiratory_JJ parameters_NNS
          returned_VBD to_TO control_VB values_NNS after_IN the_DT cessation_NN of_IN NO_DT
          inhalation_NN ._.
        
        
          Effects_NNPS of_IN septic_JJ shock_NN on_IN dose-response_JJ
          curves_NNS
          At_IN control_NN ,_, hemodynamic_JJ and_CC respiratory_JJ parameters_NNS
          were_VBD the_DT same_JJ for_IN both_DT groups_NNS ._. Dose-response_NNP curves_NNS of_IN
          inhaled_JJ NO_DT for_IN MPAP_NNP ,_, PVRI_NNP ,_, RVSWI_NNP ,_, PaCO_NNP 
          2_CD and_CC Q_NNP 
          VA_NNP /_NN Q_NNP 
          T_NN were_VBD not_RB significantly_RB different_JJ
          between_IN patients_NNS with_IN and_CC without_IN septic_JJ shock_NN (_( Figs_NNP 1_CD ,_,
          2_CD ,_, 3_LS )_) ._. As_IN shown_VBN in_IN Fig_NNP 2_CD ,_, the_DT effect_NN of_IN inhaled_JJ NO_DT on_IN PaO_NNP
          
          2_LS /_NN FiO_NNP 
          2_CD was_VBD significantly_RB increased_VBN by_IN the_DT
          presence_NN of_IN septic_JJ shock_NN ._. In_IN patients_NNS with_IN septic_JJ shock_NN ,_,
          inhaled_JJ NO_DT increased_VBN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD by_IN 190_CD %_NN ,_, the_DT maximum_NN effect_NN being_VBG
          obtained_VBN at_IN an_DT inspiratory_NN NO_DT concentration_NN of_IN 150_CD ppm_NN ._.
          In_IN patients_NNS without_IN septic_JJ shock_NN ,_, inhaled_JJ NO_DT increased_VBN
          PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD by_IN 81_CD %_NN ,_, the_DT maximum_NN effect_NN being_VBG
          obtained_VBN at_IN an_DT inspiratory_NN NO_DT concentration_NN of_IN 4_CD ._. 5_CD ppm_NN ._.
          Using_VBG a_DT two-way_JJ analysis_NN of_IN variance_NN ,_, a_DT significant_JJ
          interaction_NN was_VBD found_VBN for_IN the_DT factor_NN group_NN (_( 
          P_NN =_SYM 0_CD ._. 047_CD )_) ._.
        
        
          Individual_JJ variability_NN of_IN dose-response_JJ
          curves_NNS
          As_IN shown_VBN in_IN Figs_NNP 4_CD and_CC 5_CD ,_, dose-response_JJ curves_NNS
          demonstrated_VBN marked_VBD variability_NN between_IN individuals_NNS ._. In_IN
          patients_NNS without_IN septic_JJ shock_NN ,_, the_DT decrease_NN in_IN MPAP_NNP
          varied_VBD from_IN 11_CD to_TO 45_CD %_NN whereas_IN the_DT increase_NN in_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD varied_VBD from_IN 30_CD to_TO 220_CD %_NN (_( Fig_NNP 4_LS )_) ._. In_IN
          five_CD patients_NNS a_DT clear_JJ plateau_NN could_MD be_VB identified_VBN for_IN the_DT
          decrease_NN in_IN MPAP_NNP (_( Fig_NNP 4_CD c_SYM )_) ,_, whereas_IN MPAP_NNP continued_VBD to_TO
          decrease_VB with_IN higher_JJR NO_DT concentrations_NNS in_IN three_CD (_( Fig_NNP 4_CD a_DT )_) ._.
          Different_JJ patterns_NNS were_VBD observed_VBN for_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD :_: in_IN four_CD patients_NNS the_DT PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD ratio_NN deteriorated_VBN at_IN the_DT highest_JJS
          inspiratory_NN NO_DT concentrations_NNS (_( Fig_NNP 4_CD d_SYM )_) ,_, whereas_IN in_IN the_DT
          other_JJ four_CD PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD continued_VBD to_TO increase_VB (_( Fig_NNP 4_CD b_SYM )_) ._. The_DT
          patients_NNS whose_WP$ PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD ratio_NN continued_VBD to_TO increase_VB with_IN the_DT
          highest_JJS NO_DT concentrations_NNS demonstrated_VBD a_DT clear_JJ plateau_NN
          effect_NN in_IN MPAP_NNP at_IN NO_DT concentrations_NNS of_IN 4_CD ._. 5_CD ppm_NN suggesting_VBG
          that_IN the_DT effects_NNS of_IN NO_DT on_IN gas_NN exchange_NN and_CC pulmonary_JJ
          circulation_NN can_MD be_VB dissociated_JJ ._. In_IN patients_NNS with_IN septic_JJ
          shock_NN (_( Fig_NNP 5_LS )_) ,_, the_DT decrease_NN in_IN MPAP_NNP varied_VBD from_IN 8_CD to_TO 32_CD %_NN
          whereas_IN the_DT increase_NN in_IN PaO_NNP 
          2_CD varied_VBD from_IN 60_CD to_TO 380_CD %_NN ._. In_IN five_CD
          patients_NNS ,_, a_DT clear_JJ plateau_NN could_MD be_VB identified_VBN on_IN the_DT
          dose-response_JJ curve_NN of_IN MPAP_NNP (_( Fig_NNP cc_NN )_) whereas_IN it_PRP continued_VBD
          to_TO decrease_VB with_IN higher_JJR NO_DT concentrations_NNS in_IN three_CD (_( Fig_NNP
          4_CD a_DT )_) ._. In_IN two_CD patients_NNS ,_, PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD deteriorated_VBN at_IN the_DT highest_JJS
          inspiratory_NN NO_DT concentrations_NNS (_( Fig_NNP 5_CD d_SYM )_) whereas_IN in_IN the_DT
          other_JJ six_CD ,_, PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD continued_VBD to_TO increase_VB (_( Fig_NNP 5_CD b_SYM )_) ._. As_IN
          observed_VBD in_IN patients_NNS without_IN septic_JJ shock_NN ,_, the_DT effects_NNS of_IN
          NO_DT on_IN arterial_NN oxygenation_NN and_CC pulmonary_JJ artery_NN pressure_NN
          were_VBD dissociated_JJ ._. In_IN two_CD patients_NNS only_RB (_( patients_NNS 10_CD and_CC
          11_CD )_) ,_, dose-response_JJ curves_NNS were_VBD characterized_VBN by_IN a_DT
          concurrent_JJ dose-dependent_JJ decrease_NN in_IN MPAP_NNP and_CC an_DT
          increase_NN in_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD in_IN the_DT range_NN of_IN 0_CD ._. 15_CD to_TO 150_CD ppm_NN
          inhaled_JJ NO_UH ._.
        
        
          Toxic_JJ effects_NNS of_IN increasing_VBG concentrations_NNS of_IN
          inhaled_JJ NO_DT
          As_IN shown_VBN in_IN Table_NNP 3_CD ,_, methemoglobin_NN and_CC NO_DT 
          2_CD significantly_RB increased_VBN at_IN
          inspiratory_NN NO_DT concentrations_NNS of_IN 15_CD ppm_NN ._. A_DT mean_JJ
          intratracheal_NN NO_DT 
          2_CD concentration_NN of_IN 4_CD ±_NN 0_CD ._. 9_CD ppm_NN and_CC a_DT
          mean_JJ methemoglobin_NN concentration_NN of_IN 3_CD ._. 8_CD ±_NN 0_CD ._. 5_CD %_NN were_VBD
          observed_VBN at_IN an_DT inspiratory_NN NO_DT concentration_NN of_IN 150_CD
          ppm_NN ._.
        
      
      
        Discussion_NNP
        
          Factors_NNP influencing_VBG individual_JJ dose-response_JJ
          curves_NNS
          During_IN mechanical_JJ ventilation_NN ,_, intratracheal_NN NO_DT
          concentrations_NNS fluctuate_VBP according_VBG to_TO the_DT phase_NN of_IN
          respiration_NN [_NN 9_CD ]_NN ,_, the_DT inspiratory_NN concentration_NN being_VBG
          greater_JJR than_IN the_DT expiratory_NN concentration_NN because_IN NO_DT is_VBZ
          absorbed_VBN at_IN the_DT alveolar_NN level_NN ._. In_IN the_DT present_JJ study_NN ,_, NO_DT
          concentrations_NNS delivered_VBN to_TO the_DT patient_NN were_VBD determined_VBN
          by_IN sampling_VBG the_DT endotracheal_NN gas_NN using_VBG a_DT fast_JJ response_NN
          chemiluminescence_NN apparatus_NN in_IN order_NN to_TO accurately_RB
          measure_VB inspiratory_NN NO_DT concentration_NN [_NN 9_CD ]_NN ._. If_IN used_VBN ,_, slow_JJ
          response_NN chemiluminescence_NN would_MD have_VB underestimated_VBN the_DT
          true_JJ inspiratory_NN NO_DT concentration_NN by_IN averaging_VBG it_PRP
          together_RB with_IN the_DT expiratory_NN level_NN ,_, as_RB probably_RB occurred_VBD
          in_IN two_CD of_IN our_PRP$ previous_JJ studies_NNS [_NN 4_CD ,_, 23_CD ]_NN ._. Another_DT reason_NN
          for_IN determining_VBG the_DT inspiratory_NN NO_DT concentration_NN in_IN this_DT
          way_NN was_VBD the_DT method_NN of_IN NO_DT administration_NN used_VBN ._. Continuous_NNP
          administration_NN of_IN NO_DT through_IN the_DT initial_JJ part_NN of_IN the_DT
          inspiratory_NN limb_NN during_IN volume_NN controlled_VBD ventilation_NN
          invariably_RB results_VBZ in_IN fluctuation_NN of_IN the_DT NO_DT concentration_NN
          within_IN the_DT inspiratory_NN limb_NN due_JJ to_TO a_DT '_POS bolus_JJ '_POS effect_NN [_NN 24_CD ,_,
          25_CD ]_NN ._. Although_IN mixing_VBG of_IN NO_DT increases_NNS with_IN distance_NN from_IN
          the_DT site_NN of_IN administration_NN [_NN 24_CD ]_NN ,_, a_DT fast_JJ response_NN
          analyser_NN is_VBZ required_VBN to_TO accurately_RB measure_VB the_DT peak_NN NO_DT
          concentration_NN during_IN the_DT inspiratory_NN phase_NN ._. We_PRP previously_RB
          demonstrated_VBD in_IN an_DT in_IN vitro_NN experiment_NN ,_, that_IN the_DT NOX_NNP 4000_CD
          was_VBD able_JJ to_TO measure_VB rapid_JJ fluctuations_NNS of_IN NO_DT
          concentrations_NNS with_IN a_DT precision_NN ≥_NN 95_CD %_NN [_NN 9_CD ]_NN ._.
          In_IN the_DT present_JJ study_NN ,_, two_CD different_JJ patterns_NNS of_IN
          dose-response_JJ curves_NNS were_VBD observed_VBN ._. In_IN 10_CD patients_NNS (_( five_CD
          in_IN each_DT group_NN )_) a_DT plateau_NN effect_NN for_IN MPAP_NNP could_MD be_VB
          identified_VBN at_IN NO_DT concentrations_NNS ranging_VBG between_IN 0_CD ._. 45_CD and_CC
          4_CD ._. 5_CD ppm_NN ._. In_IN six_CD patients_NNS (_( three_CD in_IN each_DT group_NN )_) MPAP_NNP
          continued_VBD to_TO decrease_VB with_IN the_DT highest_JJS NO_DT concentrations_NNS
          (_( Figs_NNP 4_CD and_CC 5_LS )_) ._. These_DT different_JJ variation_NN profiles_NNS did_VBD not_RB
          appear_VB to_TO be_VB related_VBN to_TO the_DT presence_NN of_IN septic_JJ shock_NN ._.
          Although_IN the_DT mean_JJ pulmonary_JJ vascular_NN effect_NN of_IN inhaled_JJ
          NO_DT was_VBD not_RB affected_VBN by_IN the_DT presence_NN of_IN septic_JJ shock_NN ,_, the_DT
          resulting_VBG improvement_NN in_IN arterial_NN oxygenation_NN was_VBD of_IN a_DT
          greater_JJR magnitude_NN in_IN patients_NNS with_IN septic_JJ shock_NN (_( Fig_NNP 2_LS )_) ._.
          The_DT reasons_NNS for_IN this_DT difference_NN are_VBP not_RB clear_JJ ._. It_PRP can_MD be_VB
          hypothesized_VBN that_IN the_DT same_JJ degree_NN of_IN inhaled_JJ NO-induced_NNP
          vasodilation_NN of_IN the_DT pulmonary_JJ vessels_NNS perfusing_VBG
          ventilated_VBN lung_NN areas_NNS resulted_VBD in_IN a_DT greater_JJR
          redistribution_NN of_IN pulmonary_JJ blood_NN flow_NN in_IN patients_NNS with_IN
          septic_JJ shock_NN ._. This_DT implies_VBZ that_IN for_IN the_DT same_JJ extent_NN of_IN
          lung_NN consolidation_NN ,_, basal_NN pulmonary_JJ blood_NN flow_NN perfusing_VBG
          non-ventilated_JJ lung_NN areas_NNS was_VBD greater_JJR in_IN patients_NNS with_IN
          septic_JJ shock_NN ._. As_IN a_DT matter_NN of_IN fact_NN ,_, although_IN the_DT
          percentage_NN of_IN lung_NN consolidation_NN tended_VBD to_TO be_VB greater_JJR in_IN
          patients_NNS without_IN septic_JJ shock_NN (_( 63_CD 
          vs_NNS 57_CD %_NN )_) ,_, their_PRP$ mean_NN PaO_NNP 
          2_CD tended_VBD to_TO be_VB higher_JJR (_( 95_CD ±_NN 16_CD 
          vs_NNS 88_CD ±_NN 11_CD mmHg_NN )_) ,_, suggesting_VBG some_DT
          degree_NN of_IN hypoxic_JJ pulmonary_JJ vasoconstriction_NN impairment_NN
          in_IN the_DT non-ventilated_JJ lung_NN areas_NNS of_IN patients_NNS with_IN septic_JJ
          shock_NN ._. It_PRP is_VBZ well_RB known_VBN that_IN acute_JJ lung_NN infection_NN and_CC
          septic_JJ shock_NN may_MD impair_VB hypoxic_JJ pulmonary_JJ
          vasoconstriction_NN through_IN the_DT massive_JJ release_NN from_IN
          activated_VBN endothelium_NN of_IN vasodilating_VBG mediators_NNS such_JJ as_IN
          prostaglandins_NNS and_CC endogenous_JJ NO_DT ,_, and_CC hence_RB result_VB in_IN
          disproportionately_RB high_JJ shunting_VBG and_CC hypoxemia_NN [_NN 26_CD ,_, 27_CD ,_,
          28_CD ,_, 29_CD ,_, 30_CD ,_, 31_CD ,_, 32_CD ]_NN ._. In_IN addition_NN ,_, exogenous_JJ
          catecholamines_NNS ,_, used_VBN to_TO maintain_VB arterial_NN pressure_NN during_IN
          septic_JJ shock_NN ,_, interfere_VB with_IN hypoxic_JJ pulmonary_JJ
          vasoconstriction_NN :_: vasodilators_NNS like_IN isoproterenol_NN or_CC
          dobutamine_NN tend_VBP to_TO inhibit_VB hypoxic_JJ pulmonary_JJ
          vasoconstriction_NN whereas_IN vasoconstrictors_NNS like_IN dopamine_NN ,_,
          epinephrine_NN or_CC norepinephrine_NN tend_VBP to_TO reinforce_VB hypoxic_JJ
          pulmonary_JJ vasoconstriction_NN ._. In_IN the_DT present_JJ study_NN ,_,
          patients_NNS with_IN circulatory_NN shock_NN receiving_VBG vasodilating_VBG
          inotrops_NNS were_VBD excluded_VBN in_IN order_NN to_TO eliminate_VB the_DT
          interferences_NNS between_IN these_DT agents_NNS ,_, inhaled_JJ NO_DT and_CC
          hypoxic_JJ pulmonary_JJ vasoconstriction_NN ._.
          Confirming_VBG a_DT previous_JJ study_NN [_NN 11_CD ]_NN ,_, an_DT important_JJ
          interpatient_NN variability_NN was_VBD found_VBN in_IN both_DT groups_NNS of_IN
          patients_NNS (_( Figs_NNP 4_CD and_CC 5_LS )_) ._. Several_JJ factors_NNS may_MD account_VB for_IN
          this_DT variability_NN :_: at_IN the_DT time_NN of_IN investigation_NN ,_,
          endogenous_JJ vasoconstricting_VBG mediators_NNS involved_VBN in_IN
          pulmonary_JJ artery_NN hypertension_NN were_VBD probably_RB different_JJ
          between_IN patients_NNS ._. In_IN animal_NN studies_NNS ,_, NO_DT dose-response_JJ
          curves_NNS depend_VBP on_IN the_DT model_NN of_IN acute_JJ lung_NN injury_NN and_CC on_IN
          the_DT pathophysiology_NN of_IN pulmonary_JJ artery_NN hypertension_NN [_NN
          33_CD ,_, 34_CD ,_, 35_CD ]_NN ._. In_IN patients_NNS treated_VBN with_IN extracorporeal_NN
          membrane_NN oxygenation_NN ,_, dose-response_JJ curves_NNS of_IN inhaled_JJ NO_DT
          on_IN MPAP_NNP have_VBP been_VBN found_VBN to_TO be_VB in_IN the_DT range_NN of_IN 1_CD -_: 100_CD ppm_NN [_NN
          2_CD ]_NN ._. It_PRP has_VBZ been_VBN suggested_VBN that_IN pulmonary_JJ vasoconstrictors_NNS
          are_VBP continuously_RB activated_VBN by_IN the_DT extracorporeal_NN circuit_NN
          and_CC released_VBN into_IN the_DT circulation_NN ,_, thus_RB contributing_VBG to_TO
          pulmonary_JJ hypertension_NN [_NN 36_CD ,_, 37_CD ,_, 38_CD ,_, 39_CD ]_NN ._. Therefore_RB ,_, it_PRP
          is_VBZ conceivable_JJ that_IN higher_JJR concentrations_NNS of_IN NO_DT are_VBP
          necessary_JJ to_TO obtain_VB the_DT maximum_NN effect_NN of_IN NO_DT on_IN pulmonary_JJ
          artery_NN pressure_NN ._. In_IN the_DT present_JJ study_NN ,_, dose-response_JJ
          curves_NNS in_IN the_DT range_NN of_IN 0_CD ._. 15_CD to_TO 150_CD ppm_NN were_VBD observed_VBN in_IN
          three_CD patients_NNS without_IN septic_JJ shock_NN and_CC in_IN three_CD patients_NNS
          with_IN septic_JJ shock_NN ._. By_IN analogy_NN with_IN the_DT dose-response_JJ
          curves_NNS obtained_VBN in_IN patients_NNS on_IN extracorporeal_NN membrane_NN
          oxygenation_NN ,_, it_PRP can_MD be_VB hypothesized_VBN that_IN the_DT presence_NN of_IN
          large_JJ amounts_NNS of_IN circulating_VBG pulmonary_JJ vasoconstrictors_NNS
          in_IN these_DT patients_NNS led_VBN to_TO the_DT need_NN for_IN greater_JJR NO_DT
          concentrations_NNS ._. The_DT variability_NN of_IN circulating_VBG vasoactive_JJ
          mediators_NNS from_IN one_CD day_NN to_TO another_DT has_VBZ been_VBN recently_RB
          advocated_VBN to_TO explain_VB the_DT variability_NN of_IN the_DT dose-response_JJ
          to_TO NO_DT on_IN different_JJ days_NNS in_IN the_DT same_JJ patient_NN [_NN 11_CD ]_NN ._.
          There_EX are_VBP three_CD factors_NNS that_WDT could_MD have_VB a_DT potential_JJ
          influence_NN on_IN the_DT responsiveness_NNS of_IN patients_NNS with_IN ARDS_NNP to_TO
          inhaled_JJ NO_DT :_: (_( 1_LS )_) the_DT anatomical_JJ remodeling_NN of_IN the_DT
          pulmonary_JJ circulation_NN ;_: (_( 2_LS )_) the_DT reduction_NN of_IN the_DT lung_NN
          volume_NN accessible_JJ to_TO gas_NN ,_, and_CC (_( 3_LS )_) the_DT presence_NN of_IN septic_JJ
          shock_NN ._.
          External_NNP compression_NN of_IN the_DT pulmonary_JJ vessels_NNS by_IN PEEP_NNP ,_,
          thickening_VBG of_IN pulmonary_JJ arterial_NN walls_NNS observed_VBD in_IN the_DT
          late_JJ stage_NN of_IN ARDS_NNP ,_, and_CC thrombosis_NNS [_NN 40_CD ]_NN contribute_VB to_TO
          further_VB increase_NN pulmonary_JJ artery_NN pressure_NN which_WDT becomes_VBZ
          less_JJR and_CC less_RBR sensitive_JJ to_TO inhaled_JJ NO_DT ._. If_IN the_DT alveolar_NN
          space_NN available_JJ for_IN distribution_NN of_IN NO_DT is_VBZ reduced_VBN ,_, only_RB a_DT
          small_JJ number_NN of_IN pulmonary_JJ vessels_NNS can_MD be_VB reached_VBN ,_, thus_RB
          limiting_VBG the_DT efficiency_NN of_IN NO_UH ._. Because_IN all_DT patients_NNS were_VBD
          enrolled_VBN in_IN the_DT study_NN during_IN the_DT first_JJ 5_CD days_NNS of_IN acute_JJ
          respiratory_JJ failure_NN ,_, it_PRP is_VBZ unlikely_JJ that_DT wall_NN thickening_VBG
          was_VBD an_DT important_JJ limiting_VBG factor_NN of_IN NO_DT efficiency_NN ._.
          However_RB ,_, a_DT major_JJ reduction_NN in_IN lung_NN volume_NN was_VBD likely_JJ to_TO
          account_VB for_IN the_DT limited_JJ effect_NN of_IN NO_DT observed_VBN in_IN some_DT
          patients_NNS with_IN lung_NN consolidation_NN >_NN 70_CD %_NN (_( patients_NNS 3_CD ,_, 7_CD
          and_CC 10_CD in_IN Figs_NNP 4_CD and_CC 5_LS )_) ._. Recently_RB ,_, it_PRP has_VBZ been_VBN suggested_VBN
          that_IN the_DT presence_NN of_IN septic_JJ shock_NN may_MD impair_VB
          responsiveness_NNS to_TO inhaled_JJ NO_DT [_NN 14_CD ]_NN ._. However_RB ,_, due_JJ to_TO the_DT
          small_JJ number_NN of_IN patients_NNS included_VBN in_IN this_DT study_NN and_CC the_DT
          absence_NN of_IN a_DT control_NN group_NN ,_, further_JJ studies_NNS are_VBP required_VBN
          to_TO confirm_VB this_DT interesting_JJ hypothesis_NNS ._.
          Finally_RB ,_, the_DT maximum_NN pulmonary_JJ vascular_NN effect_NN and_CC the_DT
          dose-response_JJ of_IN inhaled_JJ NO_DT on_IN pulmonary_JJ artery_NN pressure_NN
          depends_VBZ on_IN many_JJ diverse_JJ factors_NNS that_WDT may_MD be_VB associated_VBN in_IN
          a_DT given_VBN patient_NN :_: type_NN and_CC concentration_NN of_IN circulating_VBG
          pulmonary_JJ vasoconstrictors_NNS and_CC vasodilators_NNS (_( endogenous_JJ
          and_CC exogenous_JJ )_) ;_: relative_JJ importance_NN of_IN '_POS fixed_VBN '_POS and_CC
          '_POS nonfixed_JJ '_POS components_NNS of_IN pulmonary_JJ artery_NN hypertension_NN ;_:
          and_CC loss_NN of_IN lung_NN volume_NN ._. The_DT results_NNS of_IN the_DT present_JJ study_NN
          show_NN that_IN during_IN the_DT early_JJ stage_NN of_IN ARDS_NNP ,_, inspiratory_NN NO_DT
          concentrations_NNS around_IN 5_CD ppm_NN provide_VBP the_DT maximum_NN decrease_NN
          in_IN pulmonary_JJ artery_NN pressure_NN in_IN the_DT majority_NN of_IN patients_NNS
          whereas_IN higher_JJR concentrations_NNS are_VBP necessary_JJ in_IN a_DT minority_NN
          of_IN patients_NNS ._.
        
        
          Dissociation_NNP between_IN pulmonary_JJ vascular_NN effects_NNS and_CC
          effects_NNS on_IN gas_NN exchange_NN
          Quantitatively_NNP ,_, the_DT effects_NNS of_IN NO_DT on_IN pulmonary_JJ artery_NN
          pressure_NN and_CC arterial_NN oxygenation_NN were_VBD well_RB correlated_JJ in_IN
          75_CD %_NN of_IN patients_NNS ._. In_IN 11_CD subjects_NNS (_( patients_NNS 5_CD to_TO 8_CD and_CC 10_CD
          to_TO 16_CD )_) quantitative_JJ variations_NNS in_IN PaO_NNP 
          2_CD and_CC pulmonary_JJ artery_NN pressure_NN were_VBD
          in_IN agreement_NN :_: a_DT decrease_NN in_IN MPAP_NNP >_NN 20_CD %_NN of_IN the_DT control_NN
          value_NN was_VBD associated_VBN with_IN an_DT increase_NN in_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD >_NN 130_CD %_NN of_IN the_DT control_NN value_NN and_CC
          vice_NN versa_RB ._. In_IN five_CD subjects_NNS (_( patients_NNS 1_CD to_TO 4_CD and_CC patient_NN
          9_CD )_) inhaled_JJ NO-induced_NNP changes_NNS in_IN MPAP_NNP and_CC PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD were_VBD quantitatively_RB dissociated_JJ ._.
          Patient_NNP 9_CD illustrates_VBZ this_DT (_( Fig_NNP 5_LS )_) -_: although_IN among_IN
          patients_NNS with_IN septic_JJ shock_NN he_PRP had_VBD the_DT greatest_JJS NO-induced_NNP
          decrease_VB in_IN MPAP_NNP ,_, his_PRP$ PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD ratio_NN only_RB increased_VBN by_IN 70_CD %_NN ._. These_DT
          results_NNS clearly_RB suggest_VBP that_IN ,_, although_IN linked_VBN ,_, NO-induced_NNP
          pulmonary_JJ vascular_NN effects_NNS and_CC effects_NNS on_IN arterial_NN
          oxygenation_NN can_MD be_VB dissociated_JJ in_IN patients_NNS with_IN ARDS_NNP ._. In_IN
          patients_NNS with_IN septic_JJ shock_NN ,_, pulmonary_JJ arterial_NN pressure_NN
          plateaued_JJ at_IN 15_CD ppm_NN whereas_IN PaO_NNP 
          2_CD /_NN FiO_NNP 
          2_CD continued_VBD to_TO increase_VB at_IN higher_JJR NO_DT
          concentrations_NNS ._. This_DT is_VBZ in_IN apparent_JJ contrast_NN with_IN two_CD
          previous_JJ dose-response_JJ studies_NNS showing_VBG that_IN the_DT increase_NN
          in_IN PaO_NNP 
          2_CD in_IN patients_NNS with_IN ARDS_NNP generally_RB
          occurs_VBZ at_IN an_DT inspiratory_NN NO_DT concentration_NN range_NN lower_JJR
          than_IN the_DT one_CD necessary_JJ to_TO decrease_VB pulmonary_JJ artery_NN
          pressure_NN [_NN 2_CD ,_, 11_CD ]_NN ._. Further_RB ,_, undetectable_JJ changes_NNS in_IN
          pulmonary_JJ artery_NN pressure_NN may_MD induce_VB pulmonary_JJ blood_NN flow_NN
          redistribution_NN and_CC changes_NNS in_IN arterial_NN oxygenation_NN [_NN 2_CD ,_,
          3_CD ,_, 11_CD ]_NN ._. Recently_RB ,_, however_RB ,_, Lowson_NNP 
          et_CC al_NN [_NN 10_CD ]_NN found_VBD ,_, as_IN did_VBD this_DT
          study_NN ,_, that_IN PaO_NNP 
          2_CD continued_VBD to_TO increase_VB whereas_IN
          pulmonary_JJ artery_NN pressure_NN and_CC pulmonary_JJ vascular_NN
          resistance_NN plateaued_JJ at_IN NO_DT concentrations_NNS >_NN 0_CD ._. 1_CD ppm_NN ._.
          In_IN fact_NN ,_, among_IN six_CD dose-response_JJ studies_NNS already_RB
          published_VBN [_NN 2_CD ,_, 4_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ,_, 22_CD ]_NN only_RB two_CD [_NN 2_CD ,_, 11_CD ]_NN have_VBP
          suggested_VBN that_IN NO_DT concentrations_NNS required_VBN to_TO improve_VB PaO_NNP 
          2_CD are_VBP less_JJR than_IN those_DT required_JJ to_TO
          decrease_VB pulmonary_JJ artery_NN pressure_NN ._. At_IN high_JJ
          concentrations_NNS ,_, it_PRP may_MD be_VB that_IN NO_DT reaches_VBZ pulmonary_JJ
          vessels_NNS perfusing_VBG non-ventilated_JJ lung_NN areas_NNS and_CC worsens_NNS
          arterial_NN oxygenation_NN by_IN inhibiting_VBG hypoxic_JJ pulmonary_JJ
          vasoconstriction_NN as_IN observed_VBN in_IN patients_NNS 1_CD ,_, 2_CD ,_, 6_CD ,_, 8_CD and_CC
          15_CD ._. This_NNP '_POS spillover_NN '_'' of_IN NO_DT into_IN the_DT pulmonary_JJ circulation_NN
          could_MD occur_VB either_CC by_IN diffusion_NN through_IN the_DT lung_NN
          structures_NNS or_CC directly_RB by_IN transportation_NN in_IN the_DT blood_NN
          stream_NN [_NN 41_CD ]_NN ._.
          In_IN conclusion_NN ,_, in_IN patients_NNS with_IN ARDS_NNP the_DT presence_NN of_IN
          septic_JJ shock_NN treated_VBN by_IN norepinephrine_NN administration_NN
          does_VBZ not_RB modify_VB the_DT inhaled_JJ NO-induced_NNP pulmonary_JJ artery_NN
          vascular_NN effect_NN but_CC amplifies_NNS the_DT resulting_VBG improvement_NN
          in_IN arterial_NN oxygenation_NN ._. Although_IN dose-response_JJ curves_NNS
          are_VBP characterized_VBN by_IN a_DT wide_JJ inter-patient_JJ variability_NN ,_,
          90_CD %_NN of_IN the_DT pulmonary_JJ vascular_NN effect_NN is_VBZ obtained_VBN for_IN NO_DT
          concentrations_NNS ≤_NN 4_CD ._. 5_CD ppm_NN in_IN patients_NNS with_IN or_CC without_IN
          septic_JJ shock_NN ._. The_DT use_NN of_IN such_JJ low_JJ concentrations_NNS
          precludes_VBZ any_DT potential_JJ toxicity_NN due_JJ to_TO the_DT generation_NN of_IN
          high_JJ concentrations_NNS of_IN NO_DT 
          2_CD and_CC methemoglobin_NN ._. In_IN many_JJ patients_NNS ,_,
          the_DT pulmonary_JJ vascular_NN effect_NN and_CC effect_NN on_IN gas_NN exchange_NN ,_,
          although_IN linked_VBN ,_, are_VBP dissociated_JJ suggesting_VBG that_DT
          redistribution_NN of_IN pulmonary_JJ blood_NN flow_NN does_VBZ not_RB
          exclusively_RB depend_VB on_IN the_DT intensity_NN of_IN the_DT pulmonary_JJ
          vasodilating_VBG effect_NN ._. In_IN a_DT minority_NN of_IN patients_NNS ,_,
          inspiratory_NN NO_DT concentrations_NNS >_NN 5_CD ppm_NN may_MD be_VB necessary_JJ
          to_TO obtain_VB the_DT maximum_NN improvement_NN in_IN arterial_NN
          oxygenation_NN ._.
        
      
    
  
